Advertisement

Research Studies on Organ Perfusion: From the Lab to the Clinic

  • J.-L. Vincent
  • P. Van Der Linden
  • H. Zhang

Abstract

A number of important medical questions cannot be addressed in patients for several reasons. First, the population is often too heterogeneous, with intricate underlying problems. Second, patients are usually seen when the disease state is already established so that the mechanisms of its development cannot be adequately studied and early interventions are impossible. Third, the methods necessary to the study may be too mutilating to be used in patients. In other words, the risk/benefit ratio is often too high for human application.

Keywords

Septic Shock Methylene Blue Organ Perfusion Stagnant Hypoxia Disease Clinical Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stevenson GW, Hall SC, Rudnick S, Seleny FL, Stevenson HC (1990) The effect of anesthetic agents on the human immune response. Anesthesiology 72:542–552PubMedCrossRefGoogle Scholar
  2. 2.
    Friedman G, Gomez J, Shahla M, Vincent JL (1995) Mortality from septic shock: have we made progress? Am J Respir Crit Care Med 151:A494 (Abstr)Google Scholar
  3. 3.
    Sibbald WJ, Vincent JL (1995) Round table conference: clinical trials in sepsis. Crit Care Med 23:294–399CrossRefGoogle Scholar
  4. 4.
    Lefering R, Neugebauer EA (1995) Steroid controversy in sepsis and septic shock: a metaanalysis. Crit Care Med 23:1294–1303PubMedCrossRefGoogle Scholar
  5. 5.
    Zhang H, Spapen H, Nguyen DN, Benlabed M, Buurman WA, Vincent JL (1994) Protective effects of N-acetylcysteine in endotoxemia. Am J Physiol 266:H1746-H1754PubMedGoogle Scholar
  6. 6.
    Zhang H, Spapen H, Manikis P et al (1995) Tirilazad mesylate (U74006F) inhibits the effects of endotoxin in dogs. Am J Physiol 268:H1847-H1855PubMedGoogle Scholar
  7. 7.
    Zhang H, Rogiers P, Preiser JC, Spapen H, Manikis P, Vincent JL (1995) Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med (in press)Google Scholar
  8. 8.
    Range SP, Knox AJ (1995) rhDNase in cystic fibrosis (editorial). Thorax 50:321–322PubMedCrossRefGoogle Scholar
  9. 9.
    Pradier O, Gerard C, Delvaux A et al (1993) Interieukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur J Immunol 23:2700–2703PubMedCrossRefGoogle Scholar
  10. 10.
    Mark DB, Naylor CD, Hlatky MA et al (1994) Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 331: 1130–1135PubMedCrossRefGoogle Scholar
  11. 11.
    Pingleton SK (1994) The efficacy/cost ratio of new therapy: what is the physician’s fiduciary responsibility? (editorial). Chest 105:329–330PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang H, Vincent JL (1993) Oxygen extraction is altered by endotoxin during tamponade- induced stagnant hypoxia in the dog. Circ Shock 40:168–176PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • J.-L. Vincent
  • P. Van Der Linden
  • H. Zhang

There are no affiliations available

Personalised recommendations